Chronic Kidney Disease
Conditions
Keywords
N-acetylcysteine, Chronic kidney disease, eGFR, Cystatin C, proteinuria, Stage 3 chronic kidney disease
Brief summary
N-acetylcysteine is used to reduce the risk of injury to the kidney after the administration of contrast dye. The mechanism and effectiveness of this intervention is not substantiated in the literature. The investigators hypothesize that serum creatinine will be lower in patients who receive NAC compared to those who receive the placebo but serum cystatin C will not change in patients who receive NAC compared to those who receive the placebo. Also urine creatinine will increase after the administration of NAC compared to before the administration of NAC.
Interventions
DRUGN-acetylcysteine
N-acetylcysteine 1200 mg twice daily x 48 hours
DRUGPlacebo
Sponsors
The Physicians' Services Incorporated Foundation
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with an eGFR between 30-60 ml/min calculated using last available creatinine and patient weight. 2. Age \> 18 3. No known allergies to or adverse effects from NAC 4. No known scheduled radio-contrast procedures 5. No medications known to affect creatinine secretion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 hour creatinine clearance, estimated glomerular filtration rate (eGFR), proteinuria and cystatin C | — |
Countries
Canada
Outcome results
None listed